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ABSTRACT
A large number of studies have suggested that being a woman represents a poten-
tial risk factor for the development of adverse drug reactions (ADRs). The aim of
this study is to further explore the differences between men and women with
regard to reported ADRs, particularly those associated with psychotropic drugs.
We used spontaneous reports of suspected ADRs collected by Midi-Pyrenees
(France), Veneto (Italy) and Castilla y Leon (Spain) Regional Pharmacovigilance
Centres (January 2007–December 2009). All the reports including a psychotropic
medication were selected in a first step; age distribution, seriousness and type of
ADRs were compared between men and women. Reports of nonpsychotropic drugs
were similarly identified and treated. The absolute number of reports and the
proportion, considering population, were higher in women than in men. This was
observed for all reports, but was particularly higher for psychotropic drugs (592
vs. 375; P < 0.001) than for nonpsychotropics drugs (5193 vs. 4035; P < 0.001).
Antidepressants were the most reported (women, 303; men, 141; P < 0.001); the
reporting rates (number of reports divided by exposed patients in the same period,
estimated through sales data) for these drugs, however, were not significantly
different between women (0.87 cases per 10 000 treated persons per year) and
men (0.81 cases per 10 000 treated persons per year). Although there was a
higher number of reports of ADRs in women, ADR reporting rates might be similar
as highlighted by the case of antidepressants. Antidepressant ADRs in fact were
similarly reported in men and in women. Gender differences are sometimes subtle
and difficult to explore. International networks, as the one established for this
study, do contribute to better analyse problems associated with medications.
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INTRODUCT ION
Adverse drug reactions (ADRs) represent an important
public health problem; it is estimated that ADRs are
identified in approximately 10% of patients taking a
drug [1] and account for 3–6% of admissions to hospi-
tal [2–5]. It has been suggested that being a woman
represents a potential risk factor for the development of
ADRs [6–13]; in some studies, women appeared with a
1.5- to 1.7-fold higher risk of developing an ADR as
compared to men [7,11,13,14]. Although sex- and
gender-specific differences in drug susceptibility are
often assumed [10,11,15], the evidence so far is lim-
ited. Actually, sex- and gender-specific differences in
ADRs have not been systematically described; to date,
only few studies have addressed this topic and there is
only one with information coming from spontaneous
reporting programmes [9].
In particular, psychotropic drugs have been shown
to be one of the most frequently reported drug classes
to elicit an adverse reaction, both in men and in
women [14,16]. On the basis of these assumptions, the
aim of this study was to further learn the differences
between men and women with regard to reported
ADRs, particularly those associated with psychotropic
drugs.
METHODS
For the purpose, ADRs information coming from spon-
taneous reporting to the Midi-Pyrenees (France), Vene-
to (Italy) and Castilla y Leon (Spain) Regional
Pharmacovigilance Centres was used; this information
had been gathered between 1 January 2007 and 31
December 2009. All the reports comprising a psycho-
tropic medication – antipsychotics, hypnotics, anxiolyt-
ics, antidepressants or stimulants – according to the
4th level of the Anatomical Therapeutic Chemical clas-
sification (ATC) [17] were selected in a first step; age
distribution, seriousness and, for some class, type of
ADRs, were compared between men and women. Age
was subdivided into four categories: 18 years, 19–
59 years, 60–79 years and 80 years; reports were
excluded if age or sex was not stated or if age was
under 1 year (ADRs reported after in uterus exposure
during pregnancy were not considered). Seriousness
was defined according to the World Health Organiza-
tion (WHO) definition [18]; the adverse reactions
reported were coded using Preferred Terms (PTs) and
classified by System Organ Class (SOC), according to
WHO-ART hierarchy (World Health Organization
Adverse Reaction Terms) [19]. All ADRs were taken
into account if the causality was at least possible with
the algorithms used in each country. Reports of non-
psychotropic drugs were similarly identified and analy-
sed.
For all reports, we compared ratios calculated as
follows: number of women reports/number of women
inhabitants divided by number of men reports/number
of men inhabitants. The null hypothesis was that men
and women reports were equally distributed whatever
the class of drug involved in the ADRs. Distribution of
reports by age and seriousness in men and women was
also studied. Reporting rates in those actually exposed
patients and their 95% confidence intervals (CIs) were
calculated. These rates were estimated by dividing the
number of reports by the number of exposed patient-
years; the number of patient-years, in turn, was calcu-
lated from sales data expressed as defined daily dose
(DDD) per 1000 inhabitants per year – 365 DDDs
account for a patient treated per 1 year. These report-
ing rates were estimated on the assumption that the
exposed population was large and the number of ADRs
reports was small. Midi-Pyrenees consumption data
were obtained from the medical regional department of
the French Health Insurance System (Caisse Nationale
d’Assurance Maladie des Travailleurs Salaries: CNAM-TS);
Italian consumption data were obtained from Cineca
(Centro di Supercalcolo, Consorzio di Universita); and
Spanish data consumption was obtained from the CON-
CYLIA database (Sistema de Informacion de Farmacia.
Gerencia Regional de Salud de Castilla y Leon).
Descriptive statistics were used to summarize the gen-
eral characteristics of the reports for psychotropic drugs
of interest and the reference group. To compare
categorical variables between women and men, the
Pearson’s chi-squared test was used; a P-value of <0.05
was considered statistically significant. The statistical
analyses were performed with Epi-Info software (3.5.1
version).
RESULTS
After excluding those reports in which the age and/or
sex were not available and those under 1 year, a total
of 10 195 reports fulfilled established criteria and were
selected for the study (France, n = 5479; Italy,
n = 3644; Spain, n = 1072): 967 included at least one
psychotropic medication and 9228 all other nonpsy-
chotropic medications. Of those 967 psychotropic
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reports, 592 (61%) referred to women, while 375
(39%) did to men; the corresponding figures for non-
psychotropic reports were 5193 (56%) and 4035
(44%). The distribution of reports according to sex and
their ratios are shown in Table I. Number of reports per
100 000 inhabitants and year were 64, 25 and 14 for
France, Italy and Spain, respectively.
Age distributions of reports were significantly differ-
ent between men and women for all medications and
seriousness (Table II); the only exception was that in
nonserious psychotropic reports.
Antidepressant-focused analysis
The 444 antidepressant reports (women, 303; men,
141) account for 667 ADRs (women, 434; men, 233),
the number of reactions per report being higher in
men than in women (1.65 vs. 1.43). The most
reported ADRs, both for women and men, were those
classified as ‘Central and peripheral nervous system
disorders’ (e.g. dizziness, dyskinesia and vertigo)
(women, 107; men, 46) (Figure 1). The only reactions
found to be reported significantly less often in women
were those grouped into ‘Psychiatric disorders’ (e.g.
anxiety, somnolence and insomnia) (P < 0.001).
Because the number of reports was by far higher for
antidepressants (Table I), a more detailed analysis was
performed for the main drugs of this class (Table III).
Differences between number of reports for these drugs
in women (196) and in men (46) were statistically
significant (P < 0.001); women also consumed more
antidepressants than men (23.0 DDD per 1000 inhab-
itants per day vs. 12.6 DDD per 1000 inhabitants per
day). Reporting incidence per treated patients, how-
ever, was not significantly different between men (0.81
cases per 10 000 treated persons per year) and women
(0.87 cases per 10 000 treated persons per year).
DISCUSS ION
To our knowledge, this is the first multinational study
focused on differences between men and women
carried out with spontaneously reported ADRs to phar-
macovigilance systems. The opportunity to combine
data from three different areas in southern Europe has
yielded a large number of reports to analyse; in partic-
ular, those related to psychotropic medications repre-
sent almost 1000 for the 3 years considered. Although
the number of reports in these countries was different,
it does not preclude an overall analysis; in this analy-
sis, the absolute number of reports and the proportion,
referred to the population, were by far higher in
women than in men. This was observed for all type of
reports, but was particularly higher for those reports
including psychotropic than for those with nonpsycho-
tropics drugs; this is coincidental with what has been
observed in other studies [10,12,16,20–24]. At first
glance, these findings do suggest women’s propensity
to experiencing adverse drug reactions. However, in
Women Men
RatioReports
Reports per 10 000
inhabitantsa Reports
Reports per 10 000
inhabitantsa
Nonpsychotropic drugs 5193 9.96 4035 8.04 1.24
Psychotropic drugsb 592 1.14 375 0.75 1.52c
Antipsychotics 229 0.44 176 0.35 1.26
Anxiolytics 132 0.25 93 0.18 1.39
Hypnotics/sedatives 89 0.17 59 0.12 1.42
Antidepressants 303 0.58 141 0.28 2.07
Psychostimulantsd 13 0.02 8 0.02 1.00
aTotal population for the three regions, 10 227 170 inhabitants (women, 5 210 583; men, 5 016 587).
bBecause some patients took more than one psychotropic simultaneously, the sum of the number of
reports in each class (n = 1243) is higher than the total number of psychotropic reports (n = 967).
cThe corresponding data for the three regions were, respectively, 1.49 Midi-Pyrenees (women
reports = 440, women population = 1 457 696; men reports = 279, men population = 1 379 804), 1.23
Veneto (women reports = 73, women population = 2 464 895; men reports = 57, men popula-
tion = 2 367 445) and 2.00 Castilla y Leon (women reports = 79, women population = 1 287 992; men
reports = 39, men population = 1 269 338). Source: French census, http://www.insee.fr; Italian census,
http://demo.istat.it; Spanish census, http://www.ine.es.
dThey include psychostimulants, agents used for attention-deficit hyperactivity disorder and nootropics.
Table I Reports related to psychotropic
and all other nonpsychotropic drugs.
Comparison between men and women.
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the present analysis, when considering antidepressant
drug consumption, the resulting reporting rate was
only marginally higher in women but it did not signifi-
cantly differs between men and women (Table III);
actually, the overall number of reactions per report for
antidepressants was even higher in men than in
women. This could only be analysed for antidepres-
sants. These latter results are not coincidental with the
general belief of a higher susceptibility to ADRs in
women and pose the question of the real influences of
sex and gender. Certainly, reporting is not the same
than real occurrence.
The Merriam-Webster dictionary (http://www.
merriam-webster.com/dictionary) defines sex as ‘either
of the two major forms of individuals that occur in
many species and that are distinguished respectively as
female or male especially on the basis of their repro-
ductive organs or structures’; gender meanwhile is
defined as ‘the behavioral, cultural, or psychological
traits typically associated with sex’; similar definitions
can be found in the Oxford English Dictionary (http://
www.oed.com/). Thus, sex-based differences in physical
and physiological characteristics may contribute to
interindividual pharmacokinetic and pharmacodynamic
variability [15,20–31], while gender differences refer to
a person’s self-representation as male or female shaped
by the individual economic, social, political and cul-
tural status that might be of importance for the occur-
rence of ADRs [15,32]. Hence, the question as to
whether ADRs occurrence does particularly depend on
gender is controversially and ambiguously discussed in
the literature [20–23]; in the literature, in fact, there
are no clear limits between sex and gender perspec-
tives; for instance, in a recent thorough review, differ-
ences in drug toxicity between men and women are
presented as ‘gender differences’ [33].
Our current findings of a much higher number of
reports in women (Table I) and the significantly differ-
ent distribution by age and severity in men and
women (Table II) are likely to reflect the pattern of use
of certain medications, particularly psychotropics. This
was already highlighted in the European Study of the
Epidemiology of Mental Disorders (ESEMED), where a
high prevalence of common mental disorders in women
was identified [25,26]. Another plausible explanation,
closely related to being a woman, might be the
increased life expectancy that leads elderly women to
become more fragile and subject to chronic debilitating
conditions.
The finding of similar reporting rates for antidepres-
sants was not expected. In principle, as we do not have
further data upon what occurs with the other drugs,
we cannot be sure whether reporting for all of them
behave in the same manner as it does with antidepres-
sants. In any case, and even assuming similar reporting
rates, we cannot say the occurrence is the same; the
occurrence in fact might be different and then being
balanced for a differential reporting. At this regard, it is
important to underline that while occurrence can be
influenced by sex or gender, reporting – chiefly based
on occurrence – can be markedly influenced by gender
condition. Different possibilities to explain gender differ-
ences include the following: women suffering particular
diseases; women attending medical practices more
often; women complaining more than men; doctors
underestimating adverse effects in women, particularly
Table II Distribution of reports by age and seriousness.
Comparison between men and womena.
Psychotropic reports Nonpsychotropic reports
Women (%) Men (%) Women (%) Men (%)
Age
18 5 (2) 10 (6) 690 (13) 755 (19)
19–59 134 (59) 117 (66) 2132 (41) 1511 (37)
60–79 48 (21) 29 (16) 1503 (29) 1330 (33)
80 42 (18) 20 (11) 868 (17) 439 (11)
Seriousness
Serious 96 (100) 85 (100) 1945 (100) 1693 (100)
18 0 (0) 5 (6) 127 (7) 166 (10)
19–59 44 (46) 51 (60) 734 (38) 615 (38)
60–79 24 (25) 16 (19) 592 (30) 603 (37)
80 28 (29) 13 (15) 492 (25) 255 (16)
Not serious 133 (100) 91 (100) 3248 (100) 2396 (100)
18 5 (4) 5 (5) 563 (17) 589 (25)
19–59 89 (67) 67 (74) 1398 (43) 896 (37)
60–79 23 (17) 14 (15) 911 (28) 727 (30)
80 16 (12) 5 (5) 376 (12) 184 (8)
aPearson’s chi-square test: age: psychotropic male vs. psychotropic female,
P-value = 0.03; age: nonpsychotropic male vs. nonpsychotropic female,
P-value<0.001; age: psychotropic male vs. nonpsychotropic male, P-
value<0.001; age: psychotropic female vs. nonpsychotropic female, P-
value<0.001; seriousness: psychotropic male serious vs. psychotropic
female serious, P-value=0.007; seriousness: nonpsychotropic male serious
vs. nonpsychotropic female serious, P-value <0.001; seriousness: psychotro-
pic male serious vs. nonpsychotropic male serious, P-value = 0.0002;
seriousness: psychotropic female serious vs. nonpsychotropic female seri-
ous, P-value = 0.02; seriousness: psychotropic male not serious vs. psycho-
tropic female not serious, P-value = 0.3484; seriousness: nonpsychotropic
male not serious vs. nonpsychotropic female not serious, P-value<0.001;
seriousness: psychotropic male not serious vs. nonpsychotropic male not
serious, P-value<0.001; seriousness: psychotropic female not serious vs.
nonpsychotropic female not serious, P-value<0.001.
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those of psychotropic drugs, while they consider impor-
tant to detect the ADRs when occurring in men [28–
30]. To further complicate things, as doctors are men
or women, gender perspective would be present when
identifying and reporting ADRs. Thus, it is clear that
gender influence does exist, but it is difficult to assess it
as much in occurrence of ADRs as in reporting.
For the class of antidepressants, citalopram, duloxe-
tine, escitalopram, paroxetine and venlafaxine were
the drugs most frequently involved in reports; of those,
duloxetine appears with the highest ADR reporting
rate (Table III). These five antidepressants are among
the most prescribed SSRIs in Italy, France and Spain
[34–38]. Apart from this, adverse drug reactions are
important determinants of nonadherence to antidepres-
sant treatment, but their assessment is complicated by
overlap with depressive symptoms and lack of reliable
self-report measures [39]. It has been previously
reported that adverse reactions are more frequently
experienced by individuals with more severe depression
[40]; this is explained by an increased sensitivity and
attention to physical discomfort that accompanies
depressed mood.
Although pharmacovigilance, by means of spontane-
ous reporting programmes, is an essential activity for
detecting ADRs and thus for establishing the safety of a
drug, the analysis of spontaneous reports has impor-
tant limitations. The information is neither always
complete nor homogeneous; several reporting biases
have been described; under-reporting is very common
– it is estimated that only a small proportion of all
ADRs are reported [41,42]. Nevertheless, because this
is a unique and valuable material upon ADRs, it is
worthy to explore it; it permits to find clues for new
and better approaches to learning and thinking over
sex and gender differences in drug responses. All in all,
25%20%15%10%5%0%
Body as a whole - general disorders
Central and peripheral nervous system disorders
Gastro-intestinal system disorders
Heart rate and rhythm disorders
Metabolic and nutritional disorders
Neoplasm
Psychiatric disorders
Reproductive disorders, male
Respiratory system disorders
Skin and appendages disorders
Vascular (extracardiac) disorders
White cell and res disorders Men %
Women %
Figure 1 Distribution of the adverse drug reactions associated with antidepressants by organs and systems. Comparison between men
(blue) and women (red).
Number of
reports
DDD per 1000
inhabitants day
Reporting rate per 10 000 treated
patient-years (95% CI)
Women Men Women Men Women Men
Citalopram 28 11 3.05 1.23 0.99 (0.62–1.35) 0.99 (0.49–1.77)
Duloxetine 45 19 2.00 0.79 2.25 (1.59–2.91) 2.34 (1.41–3.65)
Escitalopram 40 18 7.38 3.05 0.60 (0.42–0.79) 0.66 (0.39–1.05)
Paroxetine 46 28 6.67 5.53 0.70 (0.50–0.91) 0.56 (0.35–0.76)
Venlafaxine 37 17 4.86 1.99 0.83 (0.57–1.10) 0.94 (0.55–1.51)
Total 196 93 23.96 12.59 0.87 (0.75–0.99) 0.81 (0.65–0.97)
Table III Reporting rates of the main
antidepressants. Comparison between
men and women.
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it should be stated that international networks, as the
one established for the present study, do contribute to
better analyse problems associated with medications.
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